Loading
A phase 3 trial of PM8002, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) is a phase 3 interventional study registered as NCT07361497 by Bristol-Myers Squibb, with 850 participants planned, started 2026-03-16 and due to reach its primary completion in 2030-09-18. Interventions recorded: Pumitamig, Durvalumab. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/